NO2011020I1 - Kombinasjon omfattende aliskiren, eller et farmasøytisk akseptabelt salt derav, og amlodipin, eller et farmasøytisk akseptabelt salt derav - Google Patents

Kombinasjon omfattende aliskiren, eller et farmasøytisk akseptabelt salt derav, og amlodipin, eller et farmasøytisk akseptabelt salt derav

Info

Publication number: NO2011020I1
Authority: NO; Norway
Prior art keywords: opt; substd; alkylene; cooh; mono
Prior art date: 1994-04-18

Application number

NO2011020C

Other languages

English (en)

Original Assignee

Novartis Ag

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-04-18

Filing date

2011-09-20

Publication date

2011-09-26

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=4204102&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO2011020(I1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2011-09-20 Application filed by Novartis Ag filed Critical Novartis Ag

2011-09-26 Publication of NO2011020I1 publication Critical patent/NO2011020I1/no

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
- C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
- C07D307/26—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D307/30—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D307/32—Oxygen atoms
- C07D307/33—Oxygen atoms in position 2, the oxygen atom being in its keto or unsubstituted enol form
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C237/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups
- C07C237/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton
- C07C237/20—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by amino groups having the carbon atoms of the carboxamide groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/11—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton
- C07C255/13—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms containing cyano groups and singly-bound oxygen atoms bound to the same saturated acyclic carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/16—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by singly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/18—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by doubly-bound oxygen atoms
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
- C07C271/06—Esters of carbamic acids
- C07C271/08—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms
- C07C271/10—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C271/22—Esters of carbamic acids having oxygen atoms of carbamate groups bound to acyclic carbon atoms with the nitrogen atoms of the carbamate groups bound to hydrogen atoms or to acyclic carbon atoms to carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
General Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Emergency Medicine (AREA)
Obesity (AREA)
Hematology (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Ophthalmology & Optometry (AREA)
Anesthesiology (AREA)
Biomedical Technology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Furan Compounds (AREA)
Hydrogenated Pyridines (AREA)
Pyridine Compounds (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Peptides Or Proteins (AREA)
Heterocyclic Compounds That Contain Two Or More Ring Oxygen Atoms (AREA)
Pyrrole Compounds (AREA)
Thiazole And Isothizaole Compounds (AREA)

NO2011020C 1994-04-18 2011-09-20 Kombinasjon omfattende aliskiren, eller et farmasøytisk akseptabelt salt derav, og amlodipin, eller et farmasøytisk akseptabelt salt derav NO2011020I1 (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
CH116994		1994-04-18

Publications (1)

Publication Number	Publication Date
NO2011020I1 true NO2011020I1 (no)	2011-09-26

Family

ID=4204102

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
NO19951441A NO310410B1 (no)	1994-04-18	1995-04-12	Nye <delta>-amino-<gamma>-hydroksy-<omega>-aryl- alkansyreamider, fremgangsmåte for fremstilling herav,farmasöytiske sammensetninger og mellomprodukter, samtforbindelser for anvendelse som terapeutikum
NO2007011C NO2007011I1 (no)	1994-04-18	2007-10-31	Aliskiren eller farmasoytisk akseptable salter derav
NO2009011C NO2009011I2 (no)	1994-04-18	2009-05-18	Kombinasjon omfattende aliskiren, som fri base eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid.
NO2011020C NO2011020I1 (no)	1994-04-18	2011-09-20	Kombinasjon omfattende aliskiren, eller et farmasøytisk akseptabelt salt derav, og amlodipin, eller et farmasøytisk akseptabelt salt derav

Family Applications Before (3)

Application Number	Title	Priority Date	Filing Date
NO19951441A NO310410B1 (no)	1994-04-18	1995-04-12	Nye <delta>-amino-<gamma>-hydroksy-<omega>-aryl- alkansyreamider, fremgangsmåte for fremstilling herav,farmasöytiske sammensetninger og mellomprodukter, samtforbindelser for anvendelse som terapeutikum
NO2007011C NO2007011I1 (no)	1994-04-18	2007-10-31	Aliskiren eller farmasoytisk akseptable salter derav
NO2009011C NO2009011I2 (no)	1994-04-18	2009-05-18	Kombinasjon omfattende aliskiren, som fri base eller som et farmasøytisk akseptabelt salt derav, og hydroklortiazid.

Country Status (26)

Country	Link
US (5)	US5559111A (no)
EP (1)	EP0678503B1 (no)
JP (1)	JP3240322B2 (no)
KR (1)	KR100353779B1 (no)
CN (2)	CN1266118C (no)
AT (1)	ATE183997T1 (no)
AU (1)	AU699616B2 (no)
BR (1)	BR1100656A (no)
CA (1)	CA2147056C (no)
CY (4)	CY2208B1 (no)
CZ (1)	CZ287935B6 (no)
DE (4)	DE59506707D1 (no)
DK (1)	DK0678503T3 (no)
ES (1)	ES2137478T3 (no)
FI (1)	FI118336B (no)
GR (1)	GR3031997T3 (no)
HU (2)	HUT71701A (no)
IL (1)	IL113403A (no)
LU (2)	LU91373I2 (no)
MY (1)	MY119161A (no)
NL (2)	NL300296I2 (no)
NO (4)	NO310410B1 (no)
NZ (1)	NZ270936A (no)
RU (1)	RU95105970A (no)
TW (2)	TW366341B (no)
ZA (3)	ZA953051B (no)

Families Citing this family (153)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4408534A1 (de) *	1994-03-14	1995-09-28	Hoechst Ag	Substituierte N-Ethyl-Glycinderivate zur Herstellung von PNA und PNA-/DNA-Hybriden
MY119161A (en) *	1994-04-18	2005-04-30	Novartis Ag	Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities
EP0716077A1 (de) *	1994-12-08	1996-06-12	Ciba-Geigy Ag	Aromatisch substituierte Omega-Aminoalkansäureamide und Alkansäurediamide und ihre Verwendung als Renininhibitoren
US6465650B1 (en)	1995-03-13	2002-10-15	Aventis Pharma Deutschland Gmbh	Substituted N-ethylglycine derivatives for preparing PNA and PNA/DNA hybrids
IL135314A0 (en) *	1997-12-16	2001-05-20	Warner Lambert Co	Novel amines as pharmaceutical agents
US6846799B1 (en)	1998-08-18	2005-01-25	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
US7354894B2 (en) *	1998-08-18	2008-04-08	The Regents Of The University Of California	Preventing airway mucus production by administration of EGF-R antagonists
US6423850B1 (en)	1999-06-18	2002-07-23	E.I. Du Pont De Nemours And Company	Preparation and use of gamma-butyrolactones as cross-linking agents
US6833460B2 (en) *	1999-06-18	2004-12-21	E. I. Du Pont De Nemours And Company	Preparation and use of gamma-butyrolactones as cross-linking agents
JP4580606B2 (ja)	1999-07-29	2010-11-17	シュペーデル・ファルマ・アーゲー	２−アルキル−５−ハロゲノ−ペンタ−４−エンカルボン酸およびそれの製造
EP1296912B1 (en) *	2000-07-03	2006-01-25	Speedel Pharma AG	Process for the preparation of (r)-2-alkyl-3-phenyl-1-propanols
PL212898B1 (pl) *	2000-07-05	2012-12-31	Speedel Pharma Ag	Sposób otrzymywania podstawionych amidów oktanoilowych oraz zwiazki posrednie wykorzystane w tym sposobie
ATE267800T1 (de) *	2000-07-25	2004-06-15	Speedel Pharma Ag	Verfahren zur herstellung von substituierten octanoyl-amiden
US8168616B1 (en) *	2000-11-17	2012-05-01	Novartis Ag	Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension
DE60123911T2 (de)	2000-12-14	2007-05-31	Speedel Pharma Ag	Verfahren zur Herstellung von Aryloctanoyl-amiden
JP3440082B2 (ja)	2001-02-19	2003-08-25	科学技術振興事業団	電気自動車用インホイールモーター
CN1279178C (zh)	2001-05-15	2006-10-11	斯皮德尔药品公司	通过酶水解制备取代羧酸酯的方法
EP1406862A1 (en) *	2001-06-11	2004-04-14	Elan Pharmaceuticals, Inc.	Substituted aminoalcohols useful in treatment of alzheimer's disease
AU2002363087A1 (en) *	2001-10-18	2003-05-06	Novartis Ag	Salts formed of an at1-receptor antagonist and a cardiovascular agent
US20050101638A1 (en) *	2002-11-08	2005-05-12	Webb Randy L.	Combination of organic compounds
WO2003097098A1 (en) *	2002-05-17	2003-11-27	Novartis Ag	Pharmaceutical composition comprising a renin inhibitor, a calcium channel blocker and a diuretic
GB0212410D0 (en) *	2002-05-29	2002-07-10	Novartis Ag	Organic compounds
WO2003103652A1 (en) *	2002-06-11	2003-12-18	Elan Pharmaceuticals, Inc.	METHODS OF TREATING ALZHEIMER’S DISEASE USING AROMATICALLY SUBSTITUTED ω-AMINO-ALKANOIC ACID AMIDES AND ALKANOIC ACID DIAMIDES
WO2003103653A1 (en) *	2002-06-11	2003-12-18	Elan Pharmaceuticals, Inc.	Methods of treating alzheimer's disease using aryl alkanoic acid amides
EP1539754A4 (en) *	2002-08-23	2009-02-25	Novartis Vaccines & Diagnostic	BENZIMIDAZOCHINOLINONE AND ITS USE
US7049469B2 (en)	2002-10-24	2006-05-23	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Process for preparing (R)-salbutamol
DOP2003000765A (es) *	2002-11-27	2004-05-31	Elan Fharmaceuticals Inc	Ureas substituidas y carbamatos utiles para el tratamiento de la enfermedad de alzheimer (substituted ureas and carbamates useful in the treatment of alzheimer`s disease
WO2004100871A2 (en) *	2003-05-09	2004-11-25	Pharmacia Corporation	Combination of an aldosterone receptor antagonist and a renin inhibitor
JP2007503426A (ja) *	2003-08-25	2007-02-22	ワーナー−ランバートカンパニーリミティドライアビリティーカンパニー	新規な抗微生物性アリールオキサゾリジノン化合物
CA2600973C (en) *	2003-11-26	2012-08-07	Novartis Ag	.delta.-amino-.gamma.-hydroxy-.omega.-aryl-alkanoic acid
GB0327839D0 (en) *	2003-12-01	2003-12-31	Novartis Ag	Organic compounds
PE20050596A1 (es) *	2003-12-19	2005-10-18	Novartis Ag	Microemulsion que comprende un inhibidor renina
CA2552759A1 (en) *	2004-01-22	2005-08-04	Novartis Ag	Combination of organic compounds
ES2357585T3 (es) *	2004-01-23	2011-04-27	Novartis Ag	Derivados de aminoalcoholes y su actividad como inhibidores de la renina.
AR047447A1 (es) *	2004-01-23	2006-01-18	Speedel Experimenta Ag	Compuestos derivados de amino alcohol con actividad inhibidora de la renina y su uso en composiciones farmaceuticas.
US20070191487A1 (en) *	2004-03-17	2007-08-16	Rigassi-Dietrich Petra G	Galenic formulations of organic compounds
AR048431A1 (es) *	2004-03-17	2006-04-26	Novartis Ag	Formulaciones galenicas de compuestos organicos
NZ549535A (en)	2004-03-17	2010-11-26	Novartis Ag	Use of aliskiren for treating renal and other disorders
WO2005090304A1 (en) *	2004-03-19	2005-09-29	Speedel Experimenta Ag	Organic compounds
PT1717226E (pt) *	2004-03-19	2009-04-03	Novartis Ag	Derivados de 5-amino-4-hidroxi-8-(1h-indol-5-il)-octan amida 2,7-substituída como inibidores da renina para o tratamento da hipertensão
WO2005095876A1 (en)	2004-04-01	2005-10-13	Cucumber Limited	Delivery and storage of goods
PE20060416A1 (es) *	2004-08-03	2006-06-09	Novartis Ag	Composicion de inhibidores de renina e inhibidores de proteinas de efusion
GB0419361D0 (en)	2004-08-31	2004-10-06	Novartis Ag	Organic compounds
MX2007004020A (es)	2004-10-08	2007-05-24	Novartis Ag	Uso de inhibidores de renina para la prevencion o tratamiento de disfuncion diastolica o falla cardiaca diastolica.
TW200633983A (en) *	2004-12-10	2006-10-01	Speedel Experimenta Ag	5-Amino-4-hydroxy-2-isopropyl-7-[4-methoxy-3-(3-methoxypropoxy)benzyl]-8-methyl-nonanamides
TW200631929A (en) *	2004-12-10	2006-09-16	Speedel Experimenta Ag	ω -phenyloctanamides
WO2006083924A1 (en) *	2005-02-02	2006-08-10	Vitae Pharmaceuticals, Inc.	1-acylamino-2-hydroxy-3-amino-w-arylalkanes as renin inhibitors
CN101171230A (zh) *	2005-03-11	2008-04-30	斯皮德尔实验股份公司	用作肾素抑制剂的杂环取代的链烷酰胺
AR053826A1 (es) *	2005-03-11	2007-05-23	Speedel Experimenta Ag	Compuestos organicos
ATE451345T1 (de) *	2005-03-17	2009-12-15	Basf Se	Verfahren zur herstellung von optisch aktiven 3- phenylpropionsäurederivaten und folgeprodukte davon
GB0511686D0 (en) *	2005-06-08	2005-07-13	Novartis Ag	Organic compounds
KR20080023730A (ko) *	2005-07-11	2008-03-14	노파르티스 아게	신규한 피로카테킨 유도체
EP1745778A3 (en)	2005-07-20	2007-03-07	Speedel Experimenta AG	Diaminoalcohols as therapeutic compounds
AU2006272348B2 (en)	2005-07-22	2011-06-16	Merck Frosst Canada Ltd	Renin inhibitors
EP1948654B1 (en)	2005-09-17	2009-06-24	Novartis Ag	5-amino-4-hydroxy-7- (imidazo [1,2-a] pyridin-6- ylmethyl)-8-methyl-nonamide derivatives and related compounds as renin inhibitors for the treatment of hypertension
DE602006014707D1 (de) *	2005-09-17	2010-07-15	Novartis Ag	Mit gesättigten o-heterocyclen substituierte alkansäureamide
EP1764098A1 (en) *	2005-09-17	2007-03-21	Speedel Experimenta AG	Diaminoalcohols derivatives for the treatment of Alzheimer, malaria, HIV
GB0519764D0 (en) *	2005-09-28	2005-11-09	Novartis Ag	Organic compounds
GB0521083D0 (en) *	2005-10-17	2005-11-23	Novartis Ag	Organic compounds
CA2626568A1 (en) *	2005-10-18	2007-04-26	Nicox S.A.	Renin inhibitors nitroderivatives
RU2008119687A (ru)	2005-10-21	2009-11-27	Новартис АГ (CH)	Комбинации органических соединений
GB2431646A (en) *	2005-10-25	2007-05-02	Novartis Ag	Alternative synthesis of aryl-octanoyl amide compounds
GB2431648A (en) *	2005-10-25	2007-05-02	Novartis Ag	Alternative synthesis of aryl-octanoyl amide compounds
GB2431645A (en) *	2005-10-25	2007-05-02	Novartis Ag	Alternative synthesis of aryl-octanoyl amide compounds
GB2431649A (en) *	2005-10-25	2007-05-02	Novartis Ag	Alternative synthesis of aryl-octanoyl amide compounds
GB2431642A (en) *	2005-10-25	2007-05-02	Novartis Ag	Alternative synthesis of aryl-octanoyl amide compounds
DE102005052195A1 (de) *	2005-10-28	2007-05-03	Reuter Chemischer Apparatebau Kg	Verfahren zur Herstellung von chiralen Octensäurederivaten
TW200804241A (en) *	2006-02-24	2008-01-16	Novartis Ag	New salt
GB0605688D0 (en) *	2006-03-21	2006-05-03	Novartis Ag	Organic compounds
US20100298328A1 (en) *	2006-03-31	2010-11-25	Vitae Pharmaceuticals, Inc	1-Heterocyclylamino-2-Hydroxy-3-Amino-Omega-Arylalkanes
US8084485B2 (en) *	2006-03-31	2011-12-27	Vitae Pharmaceuticals, Inc.	6-(aminoalkyl)indazoles
RU2008143055A (ru) *	2006-04-03	2010-05-10	Новартис АГ (CH)	Ингибиторы ренина, предназначенные для гипертензии
JP5231999B2 (ja)	2006-06-23	2013-07-10	第一三共株式会社	環状アミン化合物
TW200815324A (en) *	2006-06-23	2008-04-01	Daiichi Sankyo Co Ltd	Straight chain amine compound
GB0612540D0 (en)	2006-06-23	2006-08-02	Novartis Ag	Galenical formulations of organic compounds
EP2049517B1 (en)	2006-07-20	2013-11-27	Novartis AG	Amino-piperidine derivatives as cetp inhibitors
EP1911762A1 (en)	2006-10-04	2008-04-16	Speedel Experimenta AG	Amino alcohols and their use as renin inhibitors
AR063560A1 (es) *	2006-11-07	2009-02-04	Novartis Ag	Compuestos organicos
MX2009004628A (es) *	2006-11-09	2009-05-15	Novartis Ag	Sal de alisquireno con acido orotico.
EP1938812A1 (en) *	2006-12-22	2008-07-02	Speedel Pharma AG	Pharmaceutical composition using aliskiren and avosentan
EP1958666A1 (en)	2007-02-13	2008-08-20	Speedel Experimenta AG	Heterocyclic-substituted alkanamides as therapeutic compounds
WO2008113835A1 (en) *	2007-03-21	2008-09-25	Novartis Ag	Process for preparing (r or s)-5-{1-azido-3-[6-methoxy-5-(3-methoxy-propoxy)-pyridin-3-ylmethyl]-4-methyl-pentyl}-3-alkyl-dihydro-furan-2-one
EP1972335A1 (en) *	2007-03-23	2008-09-24	Krka	Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof
CA2681203A1 (en) *	2007-04-03	2008-10-09	Novartis Ag	New methods
CN101801903A (zh) *	2007-07-11	2010-08-11	帝斯曼知识产权资产管理有限公司	饱和醛的制备
US20090076062A1 (en) *	2007-09-13	2009-03-19	Juergen Klaus Maibaum	Organic Compounds
US20090082458A1 (en) *	2007-09-26	2009-03-26	Protia, Llc	Deuterium-enriched aliskiren
RU2483718C2 (ru)	2007-09-28	2013-06-10	Новартис Аг	Галеновые композиции алискирена
DE102007049039A1 (de)	2007-10-11	2009-04-16	Reuter Chemischer Apparatebau Kg	Verfahren zur Herstellung von 8-Hydrazino-8-Aryl-Octanoylderivaten und deren Verwendung
ES2381518T3 (es)	2007-11-05	2012-05-29	Novartis Ag	Derivados del 4-bencilamino-1-carboxi acil-piperidina como inhibidores de CETP útiles para el tratamiento de enfermedades tales como hiperlipidemia o arteroesclerosis
JP2011503185A (ja)	2007-11-13	2011-01-27	テバファーマシューティカルインダストリーズリミティド	ヘミフマル酸アリスキレンの多形形態及びその調製プロセス
EP2062874B1 (en)	2007-11-20	2014-12-17	KRKA, tovarna zdravil, d.d., Novo mesto	Process and intermediates for the preparation of aliskiren
CN101878199B (zh)	2007-12-03	2013-09-18	诺瓦提斯公司	用于治疗例如高血脂或动脉硬化疾病的作为cetp抑制剂的1，2-二取代的-4-苄基氨基-吡咯烷衍生物
EP2075244A1 (en)	2007-12-24	2009-07-01	DSMIP Assets B.V.	New route to building block for making renin inhibitors
US20110111021A1 (en)	2008-02-22	2011-05-12	Hanall Biopharma Co., Ltd.	Pharmaceutical preparation
EP2275093A2 (en)	2008-04-10	2011-01-19	HanAll Biopharma Co., Ltd.	Pharmaceutical formulation
KR20100135936A (ko) *	2008-05-23	2010-12-27	테바 파마슈티컬 인더스트리즈 리미티드	알리스키렌 모노푸마레이트 및 이의 제조 방법
JP2011522829A (ja) *	2008-06-06	2011-08-04	テバファーマシューティカルインダストリーズリミティド	固体状のアリスキレン遊離塩基
EP2143425A1 (de)	2008-07-11	2010-01-13	Ratiopharm GmbH	Direktverpresste Aliskiren-Tabletten
WO2010024772A1 (en) *	2008-08-29	2010-03-04	Medivir Ab	Aspartyl protease inhibitors
EP2163245A1 (en)	2008-09-10	2010-03-17	Novartis Ag	Renin inhibitors for the treatment of psoriasis
EP2189442B1 (en)	2008-11-20	2014-10-01	Krka Tovarna Zdravil, D.D., Novo Mesto	Process and intermediates for the preparation of aliskiren
RU2535090C2 (ru)	2009-01-28	2014-12-10	Новартис Аг	Галеновы препараты органических соединений
CN102046162A (zh) *	2009-02-05	2011-05-04	特瓦制药工业有限公司	阿利吉仑化合物的固态形式
EP2393489B1 (en)	2009-02-05	2014-10-08	Krka, tovarna zdravil, d.d., Novo mesto	Moisture-activated granulation process
MX2011009846A (es)	2009-03-20	2011-09-29	Novartis Ag	Formulaciones galenicas de una combinacion de dosis fija de valsartan y alisquireno.
WO2010107966A1 (en)	2009-03-20	2010-09-23	Novartis Ag	Pharmaceutical composition comprising aliskiren
US20120149895A1 (en)	2009-04-01	2012-06-14	Lek Pharmaceuticals D.D.	Process for dimethylation of active methylene groups
BR112012003255B1 (pt)	2009-08-11	2018-10-23	Novartis Ag	processo de abertura de anel de lactonas e lactamas
US20120220663A1 (en)	2009-09-03	2012-08-30	Teva Pharmaceuticals Usa, Inc.	Solid forms of aliskiren hemifumarate and processes for preparation thereof
UA108742C2 (uk)	2009-09-23	2015-06-10		Фармацевтична композиція для лікування запальних захворювань, опосередкованих mcp-1
WO2011048523A1 (en) *	2009-10-21	2011-04-28	CarboDesign LLC	Process for the manufacture of enantiomerically pure aryloctanoic acids as aliskiren
WO2011051853A1 (en) *	2009-10-29	2011-05-05	CarboDesign LLC	Manufacturing process for preparing enaniomerically pure 8- aryloctanoic acid derivatives such as aliskiren
EP2499120A4 (en) *	2009-11-09	2013-06-26	Medivir Ab	NEW 1,3-OXAZOLIDINE COMPOUNDS AND THEIR USE AS RENIN HEMMER
US20110113995A1 (en) *	2009-11-13	2011-05-19	Lindsay Corporation	Method and apparatus for planting and irrigation
US20110137047A1 (en) *	2009-12-07	2011-06-09	CarboDesign LLC	Process for enantiomerically pure 8-Aryloctanoic acids as Aliskiren
WO2011071995A2 (en)	2009-12-08	2011-06-16	Case Western Reserve University	Compounds and methods of treating ocular disorders
CN101774986B (zh)	2010-01-06	2012-03-28	浙江天宇药业股份有限公司	一种制备阿利克伦及其中间体的方法
CN102140068B (zh) *	2010-01-30	2015-03-11	浙江华海药业股份有限公司	阿利吉仑中间体3-氨基-2,2-二甲基丙酰胺的制备方法
EP2523934A1 (en) *	2010-02-10	2012-11-21	Ratiopharm GmbH	Salts of aliskiren
WO2011116115A1 (en)	2010-03-16	2011-09-22	Novartis Ag	Aliskiren composition comprising a medium chain fatty acid, their process of manufacturing
TR201002256A1 (tr) *	2010-03-24	2011-10-21	Sanovel �La� Sanay� Ve T�Caret Anon�M ��Rket�	Stabil aliskiren formülasyonları
EP2382967A1 (de)	2010-04-21	2011-11-02	ratiopharm GmbH	Aliskiren in Form einer festen Dispersion
US20110268797A1 (en)	2010-04-30	2011-11-03	Sanovel IIac Sanayi Ve Ticaret Anonim Sirketi	Multicoated aliskiren formulations
CN102241650B (zh) *	2010-05-14	2014-05-07	浙江九洲药业股份有限公司	用于制备阿立克仑的中间体化合物及相关制备方法
IT1402925B1 (it) *	2010-12-10	2013-09-27	Chemo Iberica Sa	Processo per la produzione di aliskiren
IT1400961B1 (it) *	2010-06-04	2013-07-05	Chemo Iberica Sa	Processo per la produzione di aliskiren
TW201202178A (en)	2010-06-04	2012-01-16	Chemo Iberica Sa	Process for producing Aliskiren
CN101913998A (zh) *	2010-07-06	2010-12-15	上海朴颐化学科技有限公司	4-溴-2-(3-甲氧基丙氧基)-苯甲醚的制备方法
WO2012034065A1 (en)	2010-09-09	2012-03-15	Teva Pharmaceutical Industries Ltd.	Aliskiren intermediates and a process for analyzing the purity of aliskiren
HRP20150068T1 (hr)	2010-10-19	2015-04-10	Mylan Laboratories Limited	Sinteza aliskirena
CN102001920B (zh)	2010-11-09	2013-05-15	常州制药厂有限公司	一种药物中间体的制备方法
CN102161627A (zh) *	2011-02-24	2011-08-24	中国药科大学	ω-(N取代-氨基烷基)辛酰胺
EP2551260A1 (en)	2011-07-28	2013-01-30	Chemo Ibérica, S.A.	Chemical process for opening ring compounds
CN102942477B (zh) *	2011-08-14	2015-12-02	浙江华海药业股份有限公司	辛烯酸衍生物及其制备方法
CN102351734B (zh) *	2011-09-05	2014-02-26	浙江普洛医药科技有限公司	一种阿利克仑的制备方法
WO2013045505A1 (en)	2011-09-28	2013-04-04	Novartis Ag	Biomarkers for raas combination therapy
US8703976B2 (en) *	2011-10-02	2014-04-22	Milan Soukup	Manufacturing process for 8-aryloctanoic acids such as Aliskiren
WO2013061224A1 (en)	2011-10-25	2013-05-02	Jubilant Life Sciences Limited	Process for the preparation of aliskiren
WO2013118138A1 (en)	2011-12-13	2013-08-15	Laboratories Ltd Mylan	Novel process for the preparation of renin inhibitors
CN103172533B (zh) *	2011-12-20	2016-05-04	博瑞生物医药（苏州）股份有限公司	一种阿利克仑半富马酸盐的新晶型及其制备方法和用途
CN103204834A (zh) *	2012-01-11	2013-07-17	南京欧信医药技术有限公司	阿利克伦中间体及其制备方法和应用
US9090537B2 (en)	2012-02-17	2015-07-28	Mylan Laboratories Limited	Process for the preparation of aliskiren
WO2013124868A2 (en)	2012-02-21	2013-08-29	Mylan Laboratories Limited	Solid form of aliskiren intermediate
ITMI20120354A1 (it) *	2012-03-07	2013-09-08	Friulchem Spa	Processo per la produzione di aliskirene
WO2013144979A1 (en)	2012-03-28	2013-10-03	Maylan Laboratories Ltd	Process for the preparation of aliskiren
MX2014013749A (es)	2012-05-11	2015-02-04	Novartis Ag	Dispositivo dosificador.
WO2013171767A1 (en)	2012-05-18	2013-11-21	Mylan Laboratories Limited	An improved process for the preparation of aliskiren
EP2810644A1 (en)	2013-06-06	2014-12-10	Ferrer Internacional, S.A.	Oral formulation for the treatment of cardiovascular diseases
AU2014300955B2 (en) *	2013-06-27	2019-08-22	Patheon Austria Gmbh & Co Kg	Preparation of Grignard reagents using a fluidized bed
JP2021528735A (ja)	2018-06-14	2021-10-21	アストラゼネカ・ユーケイ・リミテッドＡｓｔｒａＺｅｎｅｃａＵＫＬｉｍｉｔｅｄ	アンジオテンシンｉｉ受容体遮断薬医薬組成物による高血圧症の治療方法
CN112679448B (zh) *	2020-12-31	2022-08-19	苏州昊帆生物股份有限公司	N-(2-氨基乙基)吗啉的制备方法
CN115340472B (zh) *	2022-09-19	2024-05-07	合肥工业大学	一种谷氨酸衍生物及其合成方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4337207A (en) *	1980-09-04	1982-06-29	Regents Of The University Of California	Biologically active catecholamine derivatives
US4729985A (en) *	1985-08-09	1988-03-08	Pfizer Inc.	Renin inhibitors containing 5-amino-2,5-disubstituted-4-hydroxypentanoic acid residues
JPH02124884A (ja) *	1988-07-08	1990-05-14	Zhongguo Yixuekexueyuan Yaowo Yanjiusuo	Ｎ―置換アミド誘導体
MY119161A (en) *	1994-04-18	2005-04-30	Novartis Ag	Delta-amino-gamma-hydroxy-omega-aryl-alkanoic acid amides with enzyme especially renin inhibiting activities

1995
- 1995-03-30 MY MYPI95000816A patent/MY119161A/en unknown
- 1995-04-04 US US08/416,242 patent/US5559111A/en not_active Expired - Lifetime
- 1995-04-07 DE DE59506707T patent/DE59506707D1/de not_active Expired - Lifetime
- 1995-04-07 DE DE122009000020C patent/DE122009000020I1/de active Pending
- 1995-04-07 DK DK95810236T patent/DK0678503T3/da not_active Application Discontinuation
- 1995-04-07 EP EP95810236A patent/EP0678503B1/de not_active Expired - Lifetime
- 1995-04-07 DE DE122007000071C patent/DE122007000071I2/de active Active
- 1995-04-07 AT AT95810236T patent/ATE183997T1/de active
- 1995-04-07 ES ES95810236T patent/ES2137478T3/es not_active Expired - Lifetime
- 1995-04-10 TW TW084103730A patent/TW366341B/zh active
- 1995-04-12 FI FI951771A patent/FI118336B/fi not_active IP Right Cessation
- 1995-04-12 AU AU16421/95A patent/AU699616B2/en not_active Ceased
- 1995-04-12 NO NO19951441A patent/NO310410B1/no not_active IP Right Cessation
- 1995-04-13 CA CA002147056A patent/CA2147056C/en not_active Expired - Lifetime
- 1995-04-13 ZA ZA953051A patent/ZA953051B/xx unknown
- 1995-04-13 NZ NZ270936A patent/NZ270936A/en not_active IP Right Cessation
- 1995-04-13 ZA ZA953052A patent/ZA953052B/xx unknown
- 1995-04-13 RU RU95105970/04A patent/RU95105970A/ru unknown
- 1995-04-13 ZA ZA953050A patent/ZA953050B/xx unknown
- 1995-04-14 HU HU9501078A patent/HUT71701A/hu unknown
- 1995-04-14 HU HU9501076A patent/HU226860B1/hu active Protection Beyond IP Right Term
- 1995-04-14 CZ CZ1995976A patent/CZ287935B6/cs not_active IP Right Cessation
- 1995-04-15 TW TW084103732A patent/TW402582B/zh not_active IP Right Cessation
- 1995-04-17 CN CNB2004100346824A patent/CN1266118C/zh not_active Expired - Lifetime
- 1995-04-17 CN CNB951050370A patent/CN1153759C/zh not_active Expired - Lifetime
- 1995-04-17 KR KR1019950008959A patent/KR100353779B1/ko not_active Expired - Lifetime
- 1995-04-17 IL IL11340395A patent/IL113403A/en active Protection Beyond IP Right Term
- 1995-04-18 JP JP09253295A patent/JP3240322B2/ja not_active Expired - Lifetime
1996
- 1996-07-02 US US08/674,555 patent/US5654445A/en not_active Expired - Lifetime
- 1996-07-25 US US08/687,277 patent/US5646143A/en not_active Expired - Lifetime
- 1996-07-25 US US08/687,878 patent/US5627182A/en not_active Expired - Lifetime
1997
- 1997-02-14 US US08/800,671 patent/US5705658A/en not_active Expired - Lifetime
- 1997-05-07 BR BR1100656-0A patent/BR1100656A/pt active IP Right Grant
1999
- 1999-11-30 GR GR990403090T patent/GR3031997T3/el unknown
2000
- 2000-12-01 CY CY0000064A patent/CY2208B1/xx unknown
2007
- 2007-09-26 NL NL300296C patent/NL300296I2/nl unknown
- 2007-10-31 LU LU91373C patent/LU91373I2/fr unknown
- 2007-10-31 NO NO2007011C patent/NO2007011I1/no unknown
- 2007-10-31 CY CY200700027C patent/CY2007027I2/el unknown
2009
- 2009-04-24 NL NL300386C patent/NL300386I1/nl unknown
- 2009-05-06 LU LU91564C patent/LU91564I2/fr unknown
- 2009-05-11 CY CY2009006C patent/CY2009006I1/el unknown
- 2009-05-18 NO NO2009011C patent/NO2009011I2/no unknown
2011
- 2011-09-20 NO NO2011020C patent/NO2011020I1/no unknown
- 2011-09-27 CY CY2011015C patent/CY2011015I2/el unknown
- 2011-09-28 DE DE201112100052 patent/DE122011100052I1/de active Pending

Also Published As

Publication number	Publication date
MY119161A (en)	2005-04-30
CY2208B1 (en)	2002-11-08
NO2007011I1 (no)	2007-12-11
HUT74074A (en)	1996-10-28
HU9501076D0 (en)	1995-06-28
US5705658A (en)	1998-01-06
CA2147056A1 (en)	1995-10-19
RU95105970A (ru)	1997-01-10
DE59506707D1 (de)	1999-10-07
HK1070881A1 (en)	2005-06-30
CY2009006I2 (el)	2010-07-28
AU699616B2 (en)	1998-12-10
DE122009000020I1 (de)	2009-08-06
JPH0881430A (ja)	1996-03-26
NZ270936A (en)	1997-06-24
CY2011015I1 (el)	2014-04-09
DE122007000071I1 (de)	2008-01-31
US5627182A (en)	1997-05-06
HU9501078D0 (en)	1995-06-28
CY2007027I1 (el)	2009-11-04
DE122011100052I1 (de)	2012-01-19
NL300296I2 (nl)	2008-02-01
NO951441L (no)	1995-10-19
NO2007011I2 (no)	2011-07-25
US5559111A (en)	1996-09-24
CN1266118C (zh)	2006-07-26
CA2147056C (en)	2005-10-25
ES2137478T3 (es)	1999-12-16
TW402582B (en)	2000-08-21
ATE183997T1 (de)	1999-09-15
AU1642195A (en)	1995-10-26
NO951441D0 (no)	1995-04-12
NL300296I1 (nl)	2007-12-03
ZA953051B (en)	1995-10-18
HUT71701A (en)	1996-01-29
GR3031997T3 (en)	2000-03-31
CN1117960A (zh)	1996-03-06
NO310410B1 (no)	2001-07-02
LU91564I2 (fr)	2009-07-06
US5646143A (en)	1997-07-08
EP0678503B1 (de)	1999-09-01
CY2009006I1 (el)	2010-07-28
FI951771A0 (fi)	1995-04-12
KR100353779B1 (ko)	2003-01-08
TW366341B (en)	1999-08-11
IL113403A (en)	2001-07-24
CN1153759C (zh)	2004-06-16
CN1550491A (zh)	2004-12-01
US5654445A (en)	1997-08-05
DE122007000071I2 (de)	2009-01-02
KR950032037A (ko)	1995-12-20
FI118336B (fi)	2007-10-15
NL300386I1 (nl)	2009-07-01
CZ287935B6 (cs)	2001-03-14
CZ97695A3 (en)	1995-11-15
ZA953050B (en)	1995-11-08
DK0678503T3 (da)	2000-03-20
EP0678503A1 (de)	1995-10-25
BR1100656A (pt)	2000-06-06
JP3240322B2 (ja)	2001-12-17
NO2009011I2 (no)	2010-11-22
HU226860B1 (en)	2009-12-28
FI951771A7 (fi)	1995-10-19
LU91373I2 (fr)	2007-12-31
CY2007027I2 (el)	2009-11-04
ZA953052B (en)	1995-10-18
IL113403A0 (en)	1995-07-31
CY2011015I2 (el)	2014-04-09
NO2009011I1 (no)	2009-06-02

Publication	Publication Date	Title
NO2011020I1 (no)	2011-09-26	Kombinasjon omfattende aliskiren, eller et farmasøytisk akseptabelt salt derav, og amlodipin, eller et farmasøytisk akseptabelt salt derav
ES2084347T3 (es)	1996-05-01	Derivados de 5-heteroil-indol.
ATE165332T1 (de)	1998-05-15	Polyenderivate, diese enthaltende pharmazeutische und kosmetische zusammensetzungen und ihre verwendung
ES2108520T3 (es)	1997-12-16	Di(met)acrilatos con grupos carbonato ciclicos.
ES8505369A1 (es)	1985-06-01	Un procedimiento para la preparacion de derivados de pirimidona
ES2117678T3 (es)	1998-08-16	Derivados de eteres milbemicina, su preparacion y su aplicacion terapeutica y agroquimica.
BR9505989A (pt)	1997-12-23	Processo para preparação de aldeídos
DK0953563T3 (da)	2003-07-28	Fremgangsmåde til fremstilling af depsipeptidderivater samt hidtil ukendte intermediater derfor
ZA919079B (en)	1992-09-30	A process for the preparation of a 3-alkylated indole
PT90831A (pt)	1989-12-29	Processo para a preparacao de eteres da 2-amino-7-hidroxitetralina